Drug delivery and adherence in young children

The aim of this pilot study was to compare a the HaloLite Paediatric Nebulizer (HPN) with a pressurized metered dose inhaler and valved holding chamber (pMDI VHC, Aerochamber™) in terms of drug delivery, adherence to treatment, compliance with device, true adherence, and acceptability. Fourteen children aged 11–36 months with asthma on regular treatment with inhaled corticosteroids were enrolled into an open, randomized, crossover trial. They received budesonide for 2 weeks with each delivery system. Both devices incorporated a datalogger which recorded information on how the device was used. The HPN was preprogrammed to deliver 25 μg of budesonide to the patient. A single actuation of budesonide 200 μg was used with the pMDI VHC. The median delivered dose of budesonide was 36 μg (range, 31–45 μg; CV, 15%) for the HPN and 53 μg (range, 17–85 μg; CV, 47%) for the pMDI VHC. The median adherence was 68% (range, 11–96%) with the HPN and 71% (range, 11–100%) with the pMDI VHC. The median device compliance was 30% and 51% and the median true adherence was 23% and 36%, respectively. The shape, size, and weight of the HaloLite Paediatric Nebulizer were generally less acceptable than the shape, size, and weight of the pMDI VHC with datalogger. These results indicate that reproducible quantities of drug can be delivered to very young children using AAD™ technology such as that incorporated into the HPN. Drug delivery with the pMDI VHC was more variable, but parents preferred this device. Pediatr Pulmonol. 2004; 37:311–317. © 2004 Wiely‐Liss, Inc.